Search results: (10000)
News What Did 3 Years of Data from the Czech National COPD Database Reveal?
In December of last year, the Czech multicenter research database on COPD was completed. This was an extensive 5-year project in which researchers included 784 patients with significant chronic obstructive pulmonary disease (FEV1 ≤ 60%) from 14 centers. This represents approximately 1% of the total number of patients with this diagnosis in the Czech Republic, making the study sample fairly representative for obtaining data on treatment in Czech real practice. Three-year data are currently available. What have they shown so far? This was summarized during this year's Hradec Pulmonology Days by Dr. Jaromír Zatloukal, Ph.D., from the Clinic of Pulmonary Diseases and TB at the Faculty of Medicine, Palacký University and University Hospital Olomouc.
News Evaluation of Various VWF Concentrates Regarding Their Ability to Mediate Platelet Binding to Collagen
The study by London researchers on various VWF concentrates focused, among other things, on evaluating their ability to mediate platelet binding to collagen.
News Comparison of Efficacy and Safety of Unsaponifiable Soy and Avocado Oil and Chondroitin Sulfate in the Treatment of Knee Osteoarthritis
Osteoarthritis is the most common joint disease in adult patients, with its prevalence increasing with age, and these issues most frequently affect the knee joint. In the treatment of knee osteoarthritis (gonarthrosis), the so-called symptomatically slow-acting drugs in the treatment of osteoarthritis (SYSADOA) are used, among which unsaponifiable soy and avocado oil or chondroitin sulfate are included. The study compared the efficacy and safety of these two drugs in a 6-month therapy of gonarthrosis.
News Is Baricitinib Suitable for Long-Term Treatment of Rheumatoid Arthritis?
The nature of rheumatoid arthritis requires effective and long-term treatment. The current analysis of data from the long-term extension RA-BEYOND reveals the potential of baricitinib in maintaining low disease activity and remission with long-term use.
News Transition of Hemophilia A Patients with a History of Coagulation Factor Inhibitor to Emicizumab
During the World Federation of Hemophilia (WFH) conference, held virtually in June 2020, interesting results were presented for patients with Hemophilia A who had a history of FVIII inhibitor and are now using Emicizumab.
News The Role of Probiotics in the Prevention of Childhood Infections
Although common acute respiratory and gastrointestinal infections are a part of childhood, they pose a significant burden on families and the healthcare and social care system. An unexpected role in their prevention can be played by the gut microbiome, specifically its support through certain probiotics. However, it is necessary to choose products supported by clinical studies.
News Brentuximab Vedotin as Another Therapeutic Option in Cutaneous T-Cell Lymphoma
Current systemic treatment for patients with cutaneous T-cell lymphoma (CTCL) unfortunately has limited efficacy, achieving low response rates and short-lasting remissions. Moreover, there is no curative therapy modality for advanced stages of CTCL. However, the results of the recently concluded ALCANZA clinical trial indicate the potential of brentuximab vedotin in this indication.
News Targeted Treatment of Metastatic Breast Cancer in the 2nd Line – Experiences from Practice
The recommended treatment for metastatic HER2-positive breast cancer in the 1st line involves dual blockade of the HER2 signaling pathway using trastuzumab and pertuzumab in combination with a taxane cytostatic. After the failure of this therapy, treatment with trastuzumab emtansine (T-DM1) is recommended. However, this recommendation is not supported by a prospectively designed controlled study examining the outcomes of this therapeutic sequence. Therefore, a group of Italian authors decided to publish the results of a patient cohort treated with this sequence in real clinical practice conditions.
News Inflammation, Polyunsaturated Fatty Acids and Their Significance in the Development and Treatment of Depression
Depression is currently a highly discussed disease with a prevalence that is likely to rise. Therefore, scientists are focusing on potential causes and new treatment modalities. It has been shown that inflammation, which can be influenced by polyunsaturated fatty acids, likely plays a role in the development of the disease. Inflammation is also a possible explanation for the frequent coexistence of depression and metabolic syndrome.
News Are SGLT2 Inhibitors Only Suitable for the Treatment of Diabetes?
SGLT2 inhibitors, or gliflozins, are effective antidiabetic drugs that have shown nephroprotective and cardioprotective effects in diabetics, repeatedly demonstrated in clinical trials. At the European Cardiology Congress in September 2019 in Paris, results were presented from the DAPA-HF study, where dapagliflozin became the first SGLT2 inhibitor to show benefits in patients with heart failure with reduced ejection fraction of the left ventricle, regardless of whether they had type 2 diabetes or not. The study thus offered a completely new perspective on the treatment of heart failure.
News Programmed Cell Death as a Therapeutic Target in Chronic Lymphocytic Leukemia
One of the key steps in malignant transformation is the disruption of apoptosis. Tumor cells exploit a variety of mechanisms that allow them to evade programmed cell death. Among the drugs targeting apoptosis pathway regulators is venetoclax, a Bcl-2 protein inhibitor used in the treatment of chronic lymphocytic leukemia (CLL). Since August 2021, venetoclax in combination with obinutuzumab can newly be used as a reimbursed therapy for previously untreated patients with CLL who are not suitable for fludarabine administration.
News Physiological and Clinical Effect of Romiplostim in the Treatment of ITP
Romiplostim in the treatment of immune thrombocytopenia (ITP) has demonstrated safety and the promise of long-term remission, enabling many pediatric and adult patients to discontinue treatment and maintain a drug-free state.
News The Anti-inflammatory and Renoprotective Effect of Candesartan May Be Independent of the AT1 Receptor
Candesartan belongs to the blockers of AT1 receptors (AT1R) for angiotensin II coupled with G protein. The authors of the presented study found that the anti-inflammatory and renoprotective effect of candesartan persists even when the receptor is completely blocked. The aim of the further study was to clarify this mechanism - independent of AT1R.
News Could candesartan counteract adverse intestinal changes induced by hypertension?
An experimental study published last year was the first to show that administration of candesartan may increase the tightness of epithelial junctions in the intestinal wall and positively affect the composition of the microflora. It expands the knowledge of recently described pathophysiological changes in the gut associated with hypertension.
News INFOGRAPHIC: How does liposomal ozonized oil work in treating eye infections?
Ozonized sunflower oil exhibits antimicrobial, anti-inflammatory, and healing properties, which is why it is added to eye drops intended for infection prevention. We bring you a clear schematic of the mechanism of action of liposomal ozonized oil.
News Romiplostim brings benefit also to patients with ITP lasting less than 1 year
What is the role of second-line therapy, in this case romiplostim, in the management of adult ITP patients who have not yet reached the chronic phase of the disease?
News Efficacy and Safety of Bimekizumab in the Treatment of Moderate to Severe Plaque Psoriasis - BE READY Study Results
The interleukin 17 (IL-17) family represents a group of pro-inflammatory cytokines that play a crucial role in the pathogenesis of psoriasis. Inhibiting interleukins from this family has a significant anti-inflammatory effect and represents a promising therapeutic target for newly developed and applied drugs.
News Patient with generalized malignant melanoma treated with nivolumab in the first line
A 75-year-old patient was referred for examination at the dermato-oncology clinic of the Dermatology Clinic of VFN in September 2016. He was being treated for ICHS and had undergone prostate surgery for hyperplasia in 2013.
News Does Sacubitril/Valsartan Prevent Myocardial Remodeling in Heart Failure Patients with Type 2 Diabetes?
The PROVE-HF study demonstrated reverse myocardial remodeling in patients with chronic heart failure with reduced ejection fraction. About 30–50% of heart failure patients have type 2 diabetes mellitus (DM2). The subject of a post hoc analysis of the PROVE-HF study was to find out whether this benefit of sacubitril/valsartan can be expected in patients with DM2 as well.
News Benefits and Cost-Effectiveness of Superabsorbent Dressings in the Treatment of Venous Leg Ulcers
A recent cost-effectiveness analysis based on German data showed that using superabsorbent dressings instead of conventional dressings in the treatment of venous leg ulcers with moderate to high exudation increases the likelihood of healing, quality of life, and reduces direct healthcare costs. Similar results were found in another analysis from last year, this time using French data, comparing superabsorbent dressings with foam dressings, again in the treatment of venous leg ulcers.
News Untreated Bleeding in Hemophilia A – An Underestimated Problem? To What Extent?
How common is bleeding in hemophilia A that ultimately goes untreated? This was the focus of a recent study, the results of which were published in the journal Research and Practice in Thrombosis and Hemostasis.
News The Presence of COPD Worsens the Course of COVID-19 – Results of Epidemiological Studies
Among the at-risk populations during the current COVID-19 pandemic are older individuals and those suffering from chronic comorbidities. The presence of chronic obstructive pulmonary disease (COPD), according to available data, represents a negative prognostic factor increasing the risk of severe course and mortality.
News Efficacy and Safety of Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction
Previous studies have shown that the antidiabetic drug empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with reduced left ventricular ejection fraction (HFrEF), both in diabetics and non-diabetics. The aim of the EMPEROR-Preserved clinical trial was to supplement data on the efficacy and safety of empagliflozin in a population of patients with heart failure with preserved ejection fraction (HFpEF; EF LK > 40%).
News Improvement in social functioning of patients with schizophrenia during treatment with lurasidone
A beneficial impact on social functioning is an important outcome of schizophrenia treatment. A recently published Japanese study is the first to demonstrate the efficacy of lurasidone compared to placebo on the social functioning of patients with schizophrenia. The results are comparable to other atypical antipsychotics.